Close Menu

NEW YORK – The Centers for Medicare & Medicaid Services proposal to alter its 14-day rule has laboratories worried that key exemptions gained through a 2018 revision of the rule may be in danger.

Debate over the CMS proposal has also highlighted a divide on this issue between smaller molecular pathology outfits and large reference labs, with the former generally advocating for the rule to remain unchanged and the latter advocating for the addition of a provision they believe could reduce some administrative burdens associated with the rule.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.